Tumor grade and progesterone receptor status predict 21-gene recurrence score in early stage invasive breast carcinoma

被引:18
|
作者
Huang, Jing Li [1 ]
Kizy, Scott [1 ]
Marmor, Schelomo [1 ]
Altman, Ariella [1 ]
Blaes, Anne [2 ]
Beckwith, Heather [2 ]
Tuttle, Todd M. [1 ]
Hui, Jane Yuet Ching [1 ]
机构
[1] Univ Minnesota, Dept Surg, Mayo Mail Code 195,420 Delaware St SE, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Div Hematol Oncol & Transplantat, Mayo Mail Code 480,420 Delaware St SE, Minneapolis, MN 55455 USA
关键词
Breast cancer; 21-Gene recurrence score; Oncotype DX; Grade; Progesterone receptor; ENDOCRINE THERAPY; HISTOLOGIC GRADE; GENE-EXPRESSION; CANCER PATIENTS; ASSAY; ESTROGEN; IMPACT; CHEMOTHERAPY; VALIDATION; EQUATIONS;
D O I
10.1007/s10549-018-4955-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThe 21-gene recurrence score (RS) assay is increasingly utilized to predict the risk of recurrence in early stage estrogen receptor (ER)-positive breast cancer. We hypothesize that tumor grade and progesterone receptor (PR) status predict RS categorization.MethodsWe identified women between the ages of 18 and 74years with stage I or II, ER-positive, invasive carcinoma of the breast from the Surveillance Epidemiology End-Results database from 2010 to 2013. Multivariable logistic regression was performed to determine factors associated with high-risk RS.ResultsWe identified 42,530 patients that met inclusion criteria. Multivariable logistic regression demonstrated that grade I tumors [OR (odds ratio) 0.33, 95% CI (confidence interval) 0.31-0.37] and PR positive (PR+) status (OR 0.16, 95% CI 0.15-0.17) were significantly less likely to be associated with high-risk RS. Of patients with grade I PR+tumors, 1% was in the high-risk group by the traditional cutoffs and 4% was in the high-risk group by the TAILORx cutoffs. The percentage of patients with high-risk RS remained low for grade I PR+tumors regardless of age, race, tumor size, and lymph node status.ConclusionsWe found that grade I PR+tumors are associated a<5% probability of having high-risk RS regardless of other patient demographic or pathologic factors. This suggests that the histologic factors of grade and PR status should be taken into consideration before ordering the 21-gene recurrence score assay.
引用
收藏
页码:671 / 677
页数:7
相关论文
共 50 条
  • [21] Effect of 21-gene recurrence score in decision-making for surgery in early stage breast cancer
    Wu, San-Gang
    Zhang, Wen-Wen
    Wang, Jun
    Dong, Yong
    Chen, Yong-Xiong
    He, Zhen-Yu
    ONCOTARGETS AND THERAPY, 2019, 12 : 2071 - 2078
  • [22] Societal economics of the 21-gene Recurrence Score® in estrogen receptor-positive early-stage breast cancer in Japan
    Yamauchi, H.
    Nakagawa, C.
    Yamashige, S.
    Takei, H.
    Yagata, H.
    Yoshida, A.
    Hayashi, N.
    Hornberger, J.
    Yu, T.
    Chien, R.
    Chao, C.
    Yoshizawa, C.
    Nakamura, S.
    CANCER RESEARCH, 2012, 72
  • [23] Evaluation Oncotype DX® 21-Gene Recurrence Score and clinicopathological parameters in early stage breast cancer
    Lashen, A. L.
    Toss, M. T.
    Fadhil, W. F.
    Oni, G. O.
    Madhusudan, S. M.
    Rakha, E. R.
    JOURNAL OF PATHOLOGY, 2023, 261 : S10 - S10
  • [24] Cost-benefit analysis of a 21-gene recurrence score for early stage breast cancer in Singapore
    Lopes, G. de Lima
    Chien, R.
    Hornberger, J. C.
    BREAST, 2011, 20 : S48 - S48
  • [25] Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland
    Lillian Smyth
    Geoff Watson
    Elaine M. Walsh
    Catherine M. Kelly
    Maccon Keane
    M. John Kennedy
    Liam Grogan
    Bryan T. Hennessy
    Seamus O’Reilly
    Linda E. Coate
    Miriam O’Connor
    Cecily Quinn
    Katharina Verleger
    Olaf Schoeman
    Susan O’Reilly
    Janice M. Walshe
    Breast Cancer Research and Treatment, 2015, 153 : 573 - 582
  • [26] The 21-Gene Recurrence Score in Male Breast Cancer
    Gulisa Turashvili
    Monica Gonzalez-Loperena
    Edi Brogi
    Maura Dickler
    Larry Norton
    Monica Morrow
    Hannah Y. Wen
    Annals of Surgical Oncology, 2018, 25 : 1530 - 1535
  • [27] Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component
    Zeng, Yufei
    Gao, Weiqi
    Chen, Xiaosong
    Shen, Kunwei
    BRITISH JOURNAL OF CANCER, 2021, 124 (05) : 975 - 981
  • [28] Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component
    Yufei Zeng
    Weiqi Gao
    Xiaosong Chen
    Kunwei Shen
    British Journal of Cancer, 2021, 124 : 975 - 981
  • [29] Is Low Tumor Grade an Exclusion Criterion for the 21-Gene Recurrence Score (RS) Assay?
    Gage, Michele
    Rosman, Martin
    Mylander, Charles
    Giblin, Erica
    Tafra, Lorraine
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : 52 - 52
  • [30] The 21-Gene Recurrence Score in Male Breast Cancer
    Turashvili, Gulisa
    Gonzalez-Loperena, Monica
    Brogi, Edi
    Dickler, Maura
    Norton, Larry
    Morrow, Monica
    Wen, Hannah Y.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 (06) : 1530 - 1535